Document 77
Filed 03/28/2008
Page 1 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 2 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 3 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 4 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 5 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 6 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 7 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 8 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 9 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 10 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 11 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 12 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 13 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 14 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 15 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 16 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 17 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 18 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 19 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 20 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 21 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 22 of 23
Case 1:07-cv-00156-JJF
Document 77
Filed 03/28/2008
Page 23 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 1 of 23
Exhibit 1
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 2 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 3 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 4 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 5 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 6 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 7 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 8 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 9 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 10 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 11 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 12 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 13 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 14 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 15 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 16 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 17 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 18 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 19 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 20 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 21 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 22 of 23
Case 1:07-cv-00156-JJF
Document 77-2
Filed 03/28/2008
Page 23 of 23
Case 1:07-cv-00156-JJF
Document 77-3
Filed 03/28/2008
Page 1 of 3
Exhibit 2
Case 1:07-cv-00156-JJF
Document 77-3
Filed 03/28/2008
Page 2 of 3
Case 1:07-cv-00156-JJF
Document 77-3
Filed 03/28/2008
Page 3 of 3
Case 1:07-cv-00156-JJF
Document 77-4
Filed 03/28/2008
Page 1 of 7
Exhibit 3
Case 1:07-cv-00156-JJF
Document 77-4
Filed 03/28/2008
Page 2 of 7
Case 1:07-cv-00156-JJF
Document 77-4
Filed 03/28/2008
Page 3 of 7
Case 1:07-cv-00156-JJF
Document 77-4
Filed 03/28/2008
Page 4 of 7
Case 1:07-cv-00156-JJF
Document 77-4
Filed 03/28/2008
Page 5 of 7
Case 1:07-cv-00156-JJF
Document 77-4
Filed 03/28/2008
Page 6 of 7
Case 1:07-cv-00156-JJF
Document 77-4
Filed 03/28/2008
Page 7 of 7
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 1 of 14
Exhibit 4
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 2 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 3 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 4 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 5 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 6 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 7 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 8 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 9 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 10 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 11 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 12 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 13 of 14
Case 1:07-cv-00156-JJF
Document 77-5
Filed 03/28/2008
Page 14 of 14
Case 1:07-cv-00156-JJF
Document 77-6
Filed 03/28/2008
Page 1 of 8
Exhibit 5
Case 1:07-cv-00156-JJF
Document 77-6
Filed 03/28/2008
Page 2 of 8
Case 1:07-cv-00156-JJF
Document 77-6
Filed 03/28/2008
Page 3 of 8
Case 1:07-cv-00156-JJF
Document 77-6
Filed 03/28/2008
Page 4 of 8
Case 1:07-cv-00156-JJF
Document 77-6
Filed 03/28/2008
Page 5 of 8
Case 1:07-cv-00156-JJF
Document 77-6
Filed 03/28/2008
Page 6 of 8
Case 1:07-cv-00156-JJF
Document 77-6
Filed 03/28/2008
Page 7 of 8
Case 1:07-cv-00156-JJF
Document 77-6
Filed 03/28/2008
Page 8 of 8
Case 1:07-cv-00156-JJF
Document 77-7
Filed 03/28/2008
Page 1 of 3
Exhibit 6
Case 1:07-cv-00156-JJF
Document 77-7
Filed 03/28/2008
Page 2 of 3
Case 1:07-cv-00156-JJF
Document 77-7
Filed 03/28/2008
Page 3 of 3
Case 1:07-cv-00156-JJF
Document 77-8
Filed 03/28/2008
Page 1 of 3
Exhibit 7
Case 1:07-cv-00156-JJF
Document 77-8
Filed 03/28/2008
Page 2 of 3
AUSTIN BOSTON
BRUSSELS BUDAPEST DALLAS FRANKFURT
WEll, GOTSHAl& MANGES LLP
SILICON VALLEY OFFICE
201 REDWOOD SHORES PARKWAY
REDWOOD SHORES, CALIFORNIA 94065
(650) 802-3000 FAX: (650) 802-3100
HOUSTON LONDON
MIAMI
MUNICH
NEW YORK
PARIS PRAGUE PROVIDENCE SHANGHAI SINGAPORE WARSAW WASHINGTON, D.C.
VERNON M. WINTERS
DIRECT LINE (650) 802-3005 E-MAIL: vern.winters(gweil.com
Februar 27, 2008
VI
EMAI
Gerald Flattman, Esq.
Kirkland & Ellis LLP 153 E. 53rd Street New York, NY 10022-461 1 GFlattmannØ)kirkland. com
Re: PDL BioPharma, Inc. v. Alexion Pharmaceuticals, Inc. D. Del. Case No. 07-156
Dear Gerald:
Plaintiff, PDL BioPhara, Inc., provides the following list of claim term or phrases for, absent agreement by the paries, construction by the Court with respect to the asserted claim ofPDL's U.S. Patents Nos. 5,693,761,5,693,762, and 6,180,370.
PDL's investigation is ongoing and the defendant, Alexion
Pharmaceuticals, Inc., has not yet disclosed to PDL its list of term and claim elements
for construction. In addition, and in violation of an agreement between the paries,
defendant has failed to identify with any sort of reasonable specificity its invalidity contentions. Accordingly, PDL reserves its right to supplement, amend, or modify this disclosure.
1. "acceptor immunoglobulin";
2. "complementarity determning regions (CDRs) from a (the) donor
immunoglobulin" ;
(#289548)
Case 1:07-cv-00156-JJF
WEll, GOTSHAl & MANGES llP
Document 77-8
Filed 03/28/2008
Page 3 of 3
Gerald Flattmann, Esq.
Februar 27,2008
Page 2
3. "donor immunoglobulin";
4. "variable region framework"; and
5. "is at least 65% (70%) identical to the (sequence of the) donor
imunoglobulin heavy (light) chain variable region framework."
cc: Josy Ingersoll, Esq. (via email) Karen Jacobs Louden, Esq. (via email) Wendy Adam (via email)
(JlngersollØ)ycst.com) (KLoudenØ)NAT.com) (WAdamØ)kikland.com)
(#289548)
Case 1:07-cv-00156-JJF
Document 77-9
Filed 03/28/2008
Page 1 of 3
Exhibit 8
Case 1:07-cv-00156-JJF
Document 77-9
Filed 03/28/2008
Page 2 of 3
Case 1:07-cv-00156-JJF
Document 77-9
Filed 03/28/2008
Page 3 of 3
Case 1:07-cv-00156-JJF
Document 77-10
Filed 03/28/2008
Page 1 of 2
Exhibit 9
Case 1:07-cv-00156-JJF
Document 77-10
Filed 03/28/2008
Page 2 of 2
Case 1:07-cv-00156-JJF
Document 77-11
Filed 03/28/2008
Page 1 of 8
Exhibit 10
Case 1:07-cv-00156-JJF
Document 77-11
Filed 03/28/2008
Page 2 of 8
Case 1:07-cv-00156-JJF
Document 77-11
Filed 03/28/2008
Page 3 of 8
Case 1:07-cv-00156-JJF
Document 77-11
Filed 03/28/2008
Page 4 of 8
Case 1:07-cv-00156-JJF
Document 77-11
Filed 03/28/2008
Page 5 of 8
Case 1:07-cv-00156-JJF
Document 77-11
Filed 03/28/2008
Page 6 of 8
Case 1:07-cv-00156-JJF
Document 77-11
Filed 03/28/2008
Page 7 of 8
Case 1:07-cv-00156-JJF
Document 77-11
Filed 03/28/2008
Page 8 of 8
Case 1:07-cv-00156-JJF
Document 77-12
Filed 03/28/2008
Page 1 of 3
Exhibit 11
[email protected] 03/17/2008 12:25 PM To [email protected] cc Subject Re: PDL v. Alexion
Dear Gerald--I will as you ask pass on your request to PDL. During our conversation, you agreed with my observation that were PDL to agree to the stipulation that you request, that would certainly moot the pending motion to dismiss with respect to the unasserted claims. I also pointed out that, there being no case or controversy between the parties with respect to the unasserted claims, PDL should not have to stipulate to Alexion's non-infringement of the claims of the three patents-in-suit that have yet to be specifically asserted by PDL; Alexion has to demonstrate a case or controversy. You disagreed. I will get back to you, likely tomorrow, on this. Best regards, Vern.
***************** Vernon M. Winters Weil, Gotshal & Manges LLP Silicon Valley Office 201 Redwood Shores Parkway Redwood Shores, CA 94065 t: 650.802.3005 f: 650.802.3100 m.: 650.339.5037 w: www.weil.com
"Gerald J Flattmann Jr "
To [email protected] cc Subject PDL v. Alexion
Case 1:07-cv-00156-JJF
Document 77-12
Filed 03/28/2008
Page 3 of 3
Dear Vern: Thanks for talking this morning about PDL's pending motion to dismiss Alexion's counterclaim of invalidity as to "unasserted claims." I asked you whether PDL would be willing to stipulate to Alexion's non-infringement of the claims of the three patents-in-suit that have yet to be specifically asserted by PDL. I would be grateful if PDL would consider that question and get back to us with an answer in the next day or two. Best regards, Gerald *********************************************************** The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Kirkland & Ellis LLP or Kirkland & Ellis International LLP. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. *********************************************************** < END >
The information contained in this email message is intended only for use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by email ([email protected]), and destroy the original message. Thank you
Case 1:07-cv-00156-JJF
Document 77-13
Filed 03/28/2008
Page 1 of 3
Exhibit 12
----- Original Message ----From: vern.winters Sent: 03/20/2008 10:25 AM MST To: Gerald Flattmann Jr Subject: Re: PDL v. Alexion
Dear Gerald: We write in response to Alexion's request that PDL BioPharma stipulate that Alexion does not infringe claims that PDL has not asserted, which you correctly refer to as the "unasserted claims." The request is not appropriate. PDL has not asserted the unasserted claims against Alexion, and there is no case or controversy between the parties with respect to those claims. Best regards, Vern
***************** Vernon M. Winters Weil, Gotshal & Manges LLP Silicon Valley Office 201 Redwood Shores Parkway Redwood Shores, CA 94065 t: 650.802.3005 f: 650.802.3100 m.: 650.339.5037 w: www.weil.com
"Gerald J Flattmann Jr "
To [email protected] cc Subject PDL v. Alexion
Case 1:07-cv-00156-JJF
Document 77-13
Filed 03/28/2008
Page 3 of 3
Dear Vern: Thanks for talking this morning about PDL's pending motion to dismiss Alexion's counterclaim of invalidity as to "unasserted claims." I asked you whether PDL would be willing to stipulate to Alexion's non-infringement of the claims of the three patents-in-suit that have yet to be specifically asserted by PDL. I would be grateful if PDL would consider that question and get back to us with an answer in the next day or two. Best regards, Gerald *********************************************************** The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Kirkland & Ellis LLP or Kirkland & Ellis International LLP. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. *********************************************************** < END >
The information contained in this email message is intended only for use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by email ([email protected]), and destroy the original message. Thank you
United States Free Forms
Canada Free Forms
United Kingdom Free Forms
Australia Free Forms